
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics is a late-stage biopharmaceutical company with a positive outlook due to its strong financial position with $220.0M in cash and its novel product VIZZ, which offers a safe and effective alternative for reading glasses patients with its minimized ciliary muscle involvement. Additionally, LENZ's global expansion plans and exclusive distribution agreements provide a strong foundation for future growth potential. Risks to the investment include potential failure to achieve peak revenue estimates and securing necessary capital resources.
Bears say
LENZ Therapeutics is facing challenges in obtaining significant revenue from its recently launched VIZZ product due to lower than expected rx volume and hampered by the 9% increase since the last quarter. Furthermore, the company is facing financial struggles as evident from the increased impairment costs in the 2Q26 earnings report, leading to a potential decrease in profitability and lower stock prices in the future. Despite some initial success with around 46K filled prescriptions and the initiation of DTC campaign, the company's expansion strategy through increased sales force deployment may not have a significant impact in the short term, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares